Table 1.
Summary of ANN scores
| Biologics | Non-biologics | ||||||
|---|---|---|---|---|---|---|---|
| Anakinra | Canakinumab | Sarilumab | Tocilizumab | Methotrexate | Prednisone | ||
| Still’s disease molecular definition | +++ (81%) | +++ (86%) | +++ (85%) | +++ (85%) | − (5%) | ++ (70%) | |
| Phenotypic profiles: | |||||||
| Systemic profile | +++ (80%) | +++ (88%) | +++ (85%) | +++ (85%) | − (4%) | ++ (70%) | |
| Rheumatic profile | +++ (87%) | +++ (92%) | +++ (81%) | +++ (81%) | − (9%) | ++ (64%) | |
| Immune system components: | |||||||
| Innate immune system deregulation | ++ (71%) | ++ (71%) | + (55%) | + (55%) | − (10%) | ++ (65%) | |
| Adaptive immune system | T cell response activation | + (45%) | − (37%) | ++ (71%) | ++ (71%) | − (25%) | + (47%) |
| Defective immune regulation | − (19%) | − (37%) | + (47%) | + (47%) | − (15%) | + (50%) | |
ANN scores show the probability of the resulted relationship to be a true positive: +++ (highlighted in bold font) correspond to values > 78% (p value< 0.05); ++ correspond to values > 59% (p values < 0.15) and; + correspond to values > 38% (p value< 0.25). ANN, artificial neural network